Skip to main content
. 2018 Jun 12;77(9):1345–1353. doi: 10.1136/annrheumdis-2017-212627

Table 1.

Relative concentration of specific ACPA, anti-CCP2 and circulating immune complexes (CIC) in sera and synovial fluids

Sequence Number of patients reacting in serum (%) Serum median (mean) SF median (mean) P values
(Wilcoxon)
Compartment with highest level Serum/
IgG median (mean)
SF/
IgG median (mean)
P values
(Wilcoxon)
Compartment with highest level
Filaggrin 307–324 (CCP1) HQCHQEST(cit)GRSRGRCGRGS (cyclic) 55/77 (71) 38.89 (233.82) 17.07 (185.86) 0.0005 Serum 3.16 (22.69) 4.19 (36.59) 0.0282 SF
Vimentin 2–17 ST(cit)SVSSSSY(cit)(cit)MFGG 40/77 (52) 2.7 (14.78) −0.43 (19.40) 0.9179 0.14 (1.27) −0.11 (3.79) 0.561
Vimentin 60–75 VYAT(cit)SSAV(cit)L(cit)SSVP 48/77 (62) 36.76 (195.93) 11.5 (168.09) 0.0575 2.63 (18.14) 4.00 (36.36) 0.0009 SF
Fibrinogen α36–50 GP(cit)VVE(cit)HQSACKDS 22/77 (29) 0 (61.38) 0 (53.56) 0.1822 0 (4.67) 0 (9.67) 0.0355 SF
Fibrinogen α563–583 HHPGIAEFPS(cit)GKSSSYSKQF 47/77 (61) 10.05 (107.30) 6.48 (82.61) 0.0378 Serum 1.02 (10.51) 1.08 (18.02) 0.0216 SF
Fibrinogen α580–600 SKQFTSSTSYN(cit)GDSTFESKS 25/77 (32) 0 (43.90) 0 (27.70) 0.1398 0 (4.65) 0 (7.61) 0.5338
Fibrinogen α621–635 (cit)GHAKS(cit)PV(cit)GIHTS 36/77 (47) 0 (121.15) 0 (91.35) 0.3756 0 (13.33) 0 (20.48) 0.0987
Fibrinogen β36–52 NEEGFFSA(cit)GHRPLDKK 47/77 (61) 14.38 (156.83) 7.44 (132.73) 0.039 Serum 1.33 (13.84) 2.32 (27.04) 0.0087 SF
Fibrinogen β60–74 (cit)PAPPPISGGGY(cit)A(cit) 52/77 (68) 17.7 (170.93) 7.49 (156.08) 0.0292 Serum 1.46 (14.62) 2.40 (30.47) 0.0005 SF
Fibrinogen β62-81(Fib72) APPPISGGGY(cit)ARPAKAAAT 25/77 (32) 0 (11.19) 0 (7.09) 0.9311 0 (1.16) 0 (1.60) 0.936
Fibrinogen β62-81(Fib74) APPPISGGGYRA(cit)PAKAAAT 22/77 (29) 0.55 (35.02) 0.73 (32.12) 0.2692 0.06 (2.76) 0.11 (6.08) 0.0305 SF
α-Enolase 5-21(CEP-1) CKIHA(cit)EIFDS(cit)GNPTVEC (cyclic) 49/77 (64) 72.82 (263.44) 32.4 (235.90) 0.0183 Serum 7.85 (22.65) 6.79 (55.09) <0.0001 SF
hnRNP 1 (proprietary)* 28/77 (36) 9.79 (70.52) 6.44 (53.49) 0.0003 Serum 0.89 (6.06) 1.72 (10.64) <0.0001 SF
hnRNP 5 (proprietary)* 49/77 (64) 19.8 (134.97) 9.14 (120.27) 0.1191 1.67 (12.52) 2.36 (26.61) 0.0005 SF
hnRNP Z1 (proprietary)* 35/77 (45) 0 (65.53) 0.83 (56.09) 0.4464 0 (6.47) 0.25 (13.54) 0.0283 SF
hnRNP Z2 (proprietary)* 46/77 (60) 4.96 (128.27) 6.21 (105.07) 0.1726 0.43 (13.44) 2.75 (24.81) 0.0066 SF
hnRNP Bla26 (proprietary)* 41/77 (53) 4.57 (45.95) 0.81 (45.32) 0.2491 0.43 (4.13) 0.46 (8.74) 0.005 SF
Histone4 14–34 GAK(cit)H(cit)KVL(cit)DNIQGITKPAI 32/77 (42) 18.77 (109.76) 11.64 (81.80) <0.0001 Serum 1.66 (9.79) 2.14 (15.51) 0.0053 SF
Histone4 31–50 KPAI(cit)(cit)LA(cit)(cit)GGVK(cit)ISGLI 47/77 (61) 11.04 (101.92) 4.79 (67.97) 0.029 Serum 0.75 (10.42) 1.36 (11.51) 0.3402
Anti-CCP2 55/77 (71) 132 (317.25) 55 (153.99) <0.0001 Serum 11.60 (29.44) 10.48 (39.95) 0.0053 SF
CIC µg Eq/mL 0.53 (12.35) 0.27 (5.87) 0.0252 Serum 0.042 (1.112) 0.054 (0.914) 0.5018

Values are shown both as arbitrary units in sera and SF, as well as after correction for total IgG levels in the corresponding serum or SF samples. Comparisons were performed with the Mann-Whitney U test; significant differences are depicted in bold. The second column details the sequences of the citrullinated peptides in the multiplex assay, using the single-letter amino acid code and ‘(cit)’ for citrulline. The not listed arginine-containing control peptides have identical sequences except that they contain arginine residues instead of citrulline.

*Peptides are derived from hnRNP A3. Available on request from KS; see authors’ details.

ACPA, anti-citrullinated protein/peptide antibodies; SF, synovial fluid.